Information  X 
Enter a valid email address

Redx Pharma plc (REDX)

  Print   

Monday 13 September, 2021

Redx Pharma plc

RXC004 Phase 1 data to be presented at ESMO 2021

RNS Number : 4874L
Redx Pharma plc
13 September 2021
 

REDX PHARMA PLC

("Redx" or "the Company")

 

 

RXC004 Phase 1 monotherapy data to be presented at ESMO Congress 2021

 

Alderley Park, 13 September 2021, Redx Pharma plc (AIM: REDX), the drug discovery and development company focused on cancer and fibrosis, announces that data from the Company's RXC004 Phase 1 monotherapy study will be presented at the forthcoming European Society for Medical Oncology (ESMO) Congress, 16-21 September 2021.

 

RXC004 is the Company's lead drug candidate and is a potent, orally active porcupine inhibitor being developed as a targeted therapy for Wnt-ligand driven cancer. Based on the safety profile observed in the Phase 1 study, Redx has selected the 2mg dose of RXC004 for its planned Phase 2 monotherapy, proof of concept clinical trials which are expected to start during the second half of 2021.

 

The presentation at the ESMO Congress 2021 will be made by the Study Principal Investigator, Dr Natalie Cook, Consultant Medical Oncologist at the Christie Hospital NHS Trust, Manchester, UK.

 

Presentation No:

517MO

 

Authors:

 

N Cook, S Blagden, J Lopez, D Sarker, A Greystoke, N Harris, F Kasmi, A Naderi, G Nintos, A Ortego Franco, R Pihlak, R Shinde, L Goodwin, C Phillips, J Robertson, A Saunders, C Tilston, S Woodcock, R Plummer

 

Title:

Phase 1 study of the Porcupine (PORCN) inhibitor RXC004 in patients with advanced solid tumours

 

Day/Date:

 

Monday 20 September 2021

 

Presentation Time:

 

17:50pm to 17:55pm (CET)

 

Session Channel:

 

Channel 3

 

Session Title:

 

Developmental therapeutics

 

Session Type:

 

Mini oral session

 

Session Time:

 

17:30pm to 18:30pm (CET)

 

 

Redx to host R&D Event

 

Presented data will be discussed by Medical Experts during Redx's online R&D Event to be held on Monday 11 October 2021 at 1:00pm BST / 8.00am EDT. The event will also cover the Company's pipeline beyond RXC004.

 

To register for the event, please email [email protected] .

 

 

For further information, please contact:




Redx Pharma Plc 

UK Headquarters

Lisa Anson, Chief Executive Officer

 

 

T: +44 1625 469 918

Karl Hård, Head of Investor Relations


US Office

Peter Collum, Chief Financial Officer


SPARK Advisory Partners (Nominated Adviser)

 T: +44 203 368 3550

Matt Davis/Adam Dawes




WG Partners LLP (Joint Broker)

T: +44 20 3705 9330

Claes Spång/Nigel Birks/David Wilson




Panmure Gordon (UK) Limited (Joint Broker)

T: +44 20 7886 2500

Rupert Dearden/Freddy Crossley/Emma Earl






FTI Consulting

T: +44 20 3727 1000

Simon Conway/Ciara Martin


 

About Redx Pharma Plc

 

Redx Pharma (AIM:REDX) is focused on the discovery and development of novel targeted medicines for the treatment of cancer and fibrotic diseases, aiming initially to progress them to clinical proof of concept, before evaluating options for further development and potential value creation. Redx's lead oncology asset, RXC004, is currently in a Phase 1 study in patients with advanced malignancies and intends to  initiate multiple Phase 2 studies in H2 2021. The Company's selective ROCK2 inhibitor, RXC007, is in development for idiopathic pulmonary fibrosis and recently commenced a Phase 1 clinical study in June 2021 where headline results are expected in H1 2022. 

 

The Company has a strong track record of discovering new drug candidates through its core capability of converting medicinal chemistry insights into differentiated and commercially attractive drug candidates, and has previously completed preclinical asset transactions with Loxo Oncology (now Eli Lilly), AstraZeneca and Jazz Pharmaceuticals. 

 

To subscribe to RNS announcements from Redx, please visit: https://www.redxpharma.com/investor-centre/email-alerts

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
MSCSFLEEEEFSEEU

a d v e r t i s e m e n t